ArticleNeuroepidemiology2026
Epidemiological Trends of Idiopathic Epilepsy in Asia: 1990-2021 - An Analysis from the Global Burden of Disease Study 2021.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of the study was to evaluate the incidence, mortality, and disability-adjusted life years associated with idiopathic epilepsy in Asian region from 1990 to 2021, explore the influencing factors, and assess differences between countries, while also predicting prevalence and incidence trends of idiopathic epilepsy in Asian region up to 2036.
methodsBased on the Global Burden of Disease (GBD) database, Joinpoint regression was used to analyze temporal trends. The age-period-cohort model was employed to analyze the effects of different factors. Das Gupta's decomposition method was used to evaluate the contributions of demographic and epidemiological factors. Data envelopment analysis was performed to assess the relationship between disease burden and sociodemographic index (SDI). ARIMA and Bayesian APC models were used to predict incidence rates from 2022 to 2036 based on historical trends.
resultsIn 2021, the incidence of idiopathic epilepsy in Asia was 1,494,996.042 (95% UI: 1,096,849.405∼1,886,986.598), with an age-standardized incidence rate (ASIR) of 34.035/100,000. Saudi Arabia had the highest ASIR (67.05/100,000), while Democratic People's Republic of Korea had the lowest (21.737/100,000). From 1990 to 2021, the global ASIR of idiopathic epilepsy showed an overall increasing trend with fluctuations. The increase in incidence was mainly driven by population growth. The incidence rate was generally higher in males than in females. With increasing SDI, the DALY rate generally decreased, but there is still room for improvement in some countries. The degree of inequality between high and low SDI regions decreased but still exists to some extent. Based on the identified historical patterns and model projections, the incidence rate is expected to continue rising through 2036.
conclusionsThe burden of idiopathic epilepsy in Asia shows an increasing trend with significant regional differences. Attention should be focused on high-risk populations, strengthening the balanced allocation of medical resources between regions and formulating targeted prevention and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.